Cargando…

Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer

We aim to determine the clinical usefulness of pre-operative serum vascular endothelial growth factor (VEGF) as a predictor of outcome in patients undergoing curative resection for colorectal cancer. Serum VEGF was assayed by quantitative ELISA in 81 patients prior to curative resection for node-neg...

Descripción completa

Detalles Bibliográficos
Autores principales: Chin, K-F, Greenman, J, Gardiner, E, Kumar, H, Topping, K, Monson, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363412/
https://www.ncbi.nlm.nih.gov/pubmed/11076648
http://dx.doi.org/10.1054/bjoc.2000.1508
_version_ 1782153698423603200
author Chin, K-F
Greenman, J
Gardiner, E
Kumar, H
Topping, K
Monson, J
author_facet Chin, K-F
Greenman, J
Gardiner, E
Kumar, H
Topping, K
Monson, J
author_sort Chin, K-F
collection PubMed
description We aim to determine the clinical usefulness of pre-operative serum vascular endothelial growth factor (VEGF) as a predictor of outcome in patients undergoing curative resection for colorectal cancer. Serum VEGF was assayed by quantitative ELISA in 81 patients prior to curative resection for node-negative (n = 53) and node-positive (n = 28) disease. Median follow-up for patients without cancer death was 27 months (range 21–37). Pre-operative serum VEGF was significantly higher in patients who went on to develop metastases than those who did not (median, 713 pg ml–1 vs. 314 pg ml–1, P < 0.0001). Using multivariate Cox regression analysis, pre-operative serum VEGF was the most important prognostic factor independent of nodal status and adjuvant chemotherapy, and was superior to nodal status in predicting outcome (P < 0.00001). At 575 pg ml–1, pre-operative serum VEGF was 64% sensitive and 89% specific in predicting the development of metastases in curative resections, with a positive predictive value of 73% and a negative predictive value of 85%. Pre-operative serum VEGF is a powerful predictor of outcome following curative surgery for colorectal cancer. These data support the measurement of pre-operative serum VEGF as a method for selecting patients who require adjuvant therapy. © 2000 Cancer Research Campaign http://www.bjcancer.com
format Text
id pubmed-2363412
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23634122009-09-10 Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer Chin, K-F Greenman, J Gardiner, E Kumar, H Topping, K Monson, J Br J Cancer Regular Article We aim to determine the clinical usefulness of pre-operative serum vascular endothelial growth factor (VEGF) as a predictor of outcome in patients undergoing curative resection for colorectal cancer. Serum VEGF was assayed by quantitative ELISA in 81 patients prior to curative resection for node-negative (n = 53) and node-positive (n = 28) disease. Median follow-up for patients without cancer death was 27 months (range 21–37). Pre-operative serum VEGF was significantly higher in patients who went on to develop metastases than those who did not (median, 713 pg ml–1 vs. 314 pg ml–1, P < 0.0001). Using multivariate Cox regression analysis, pre-operative serum VEGF was the most important prognostic factor independent of nodal status and adjuvant chemotherapy, and was superior to nodal status in predicting outcome (P < 0.00001). At 575 pg ml–1, pre-operative serum VEGF was 64% sensitive and 89% specific in predicting the development of metastases in curative resections, with a positive predictive value of 73% and a negative predictive value of 85%. Pre-operative serum VEGF is a powerful predictor of outcome following curative surgery for colorectal cancer. These data support the measurement of pre-operative serum VEGF as a method for selecting patients who require adjuvant therapy. © 2000 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2000-12 2000-11-22 /pmc/articles/PMC2363412/ /pubmed/11076648 http://dx.doi.org/10.1054/bjoc.2000.1508 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Chin, K-F
Greenman, J
Gardiner, E
Kumar, H
Topping, K
Monson, J
Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer
title Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer
title_full Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer
title_fullStr Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer
title_full_unstemmed Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer
title_short Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer
title_sort pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363412/
https://www.ncbi.nlm.nih.gov/pubmed/11076648
http://dx.doi.org/10.1054/bjoc.2000.1508
work_keys_str_mv AT chinkf preoperativeserumvascularendothelialgrowthfactorcanselectpatientsforadjuvanttreatmentaftercurativeresectionincolorectalcancer
AT greenmanj preoperativeserumvascularendothelialgrowthfactorcanselectpatientsforadjuvanttreatmentaftercurativeresectionincolorectalcancer
AT gardinere preoperativeserumvascularendothelialgrowthfactorcanselectpatientsforadjuvanttreatmentaftercurativeresectionincolorectalcancer
AT kumarh preoperativeserumvascularendothelialgrowthfactorcanselectpatientsforadjuvanttreatmentaftercurativeresectionincolorectalcancer
AT toppingk preoperativeserumvascularendothelialgrowthfactorcanselectpatientsforadjuvanttreatmentaftercurativeresectionincolorectalcancer
AT monsonj preoperativeserumvascularendothelialgrowthfactorcanselectpatientsforadjuvanttreatmentaftercurativeresectionincolorectalcancer